<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04523168</url>
  </required_header>
  <id_info>
    <org_study_id>20-006386</org_study_id>
    <nct_id>NCT04523168</nct_id>
  </id_info>
  <brief_title>Feasibility and Efficacy of Coronary Sinus Narrowing in Patients With Coronary Microvascular Dysfunction</brief_title>
  <acronym>Reducer</acronym>
  <official_title>A Phase II Study Testing the Feasibility and Efficacy of Coronary Sinus Narrowing in Patients With Coronary Microvascular Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amir Lerman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to evaluate the role of a novel implantable device, called The&#xD;
      Neovasc Reducer™ System, in improving microvascular function, symptoms and quality of life in&#xD;
      symptomatic patients with coronary microvascular dysfunction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2021</start_date>
  <completion_date type="Anticipated">January 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Coronary Flow Reserve (CFR)</measure>
    <time_frame>Baseline, 4 months post Reducer implantation</time_frame>
    <description>Calculated as the ratio of hyperemic to rest coronary blood flow</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Index of Myocardial Resistance (IMR)</measure>
    <time_frame>Baseline, 4 months post Reducer implantation</time_frame>
    <description>Calculated as the ratio of coronary pressure divided by coronary blood flow at maximal hyperemia</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Coronary Microvascular Dysfunction</condition>
  <arm_group>
    <arm_group_label>Chronic Refractory Angina</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with chronic refractory angina will undergo implantation of the Neovasc Reducer™ System in the cardiac catheterization laboratory.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The Neovasc Reducer™ System</intervention_name>
    <description>A stainless-steel mesh pre-mounted on a customized hourglass shaped balloon catheter, is designed to create a focal narrowing in the lumen of the CS to generate a pressure gradient across it.</description>
    <arm_group_label>Chronic Refractory Angina</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Age &gt;18&#xD;
&#xD;
          -  Able to provide written informed consent and willing to participate in all required&#xD;
             study follow-up assessments&#xD;
&#xD;
          -  Symptomatic CAD with refractory angina defined as CCS class II to IV, despite optimal&#xD;
             tolerated medical therapy&#xD;
&#xD;
          -  Abnormal coronary microvascular function indices: CFR≤2.5 and/or IMR≥25&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Recent (within 3 months) acute coronary syndrome&#xD;
&#xD;
          -  Recent (within 6 months) percutaneous coronary intervention revascularization by stent&#xD;
&#xD;
          -  Patients with prior coronary artery bypass surgery&#xD;
&#xD;
          -  Unstable angina (recent onset angina, crescendo angina, or rest angina with ECG&#xD;
             changes) during the last 30 days&#xD;
&#xD;
          -  Subjects in cardiogenic shock (systolic pressure &lt; 80mm/Hg, on vasopressors or&#xD;
             intraaortic counter pulsation) at the time of consenting. Subjects who recover from&#xD;
             cardiogenic shock by the time of consenting are eligible.&#xD;
&#xD;
          -  Obstructive CAD on coronary angiography (&gt;70% stenosis or 50-70% stenosis with&#xD;
             iFR&lt;0.89 or FFR&lt;0.8 in epicardial artery)&#xD;
&#xD;
          -  Inability to perform invasive coronary flow evaluation and/or measure CFR and IMR in&#xD;
             the LAD&#xD;
&#xD;
          -  Severe valvular heart disease&#xD;
&#xD;
          -  LVEF&lt;30%&#xD;
&#xD;
          -  Decompensated congestive heart failure (CHF) or hospitalizatoin due to CHF during the&#xD;
             last 3 months&#xD;
&#xD;
          -  Patient with a pacemaker electrode in the CS&#xD;
&#xD;
          -  Mean right atrial pressure &gt;15 mmHg&#xD;
&#xD;
          -  Anomalous or abnormal CS anatomy (e.g., tortuosity, aberrant branch, persistent left&#xD;
             superior vena cava (SVC) as demonstrated on angiogram&#xD;
&#xD;
          -  CS diameter at the site of planned implantation greater than 13mm or less than 9.5 mm&#xD;
             as measured by angiogram&#xD;
&#xD;
          -  Severe chronic obstructive pulmonary disease (COPD) indicated by a forced expiratory&#xD;
             volume in one second that is less than 55 percent of the predicted value&#xD;
&#xD;
          -  Tricuspid valve replacement or repair (tissue or mechanical)&#xD;
&#xD;
          -  Chronic renal failure (serum creatinine &gt;2mg/dL), and or on chronic hemodialysis&#xD;
&#xD;
          -  Moribund, or with comorbidities limiting life expectancy to less than one year&#xD;
&#xD;
          -  Known severe reaction to required procedural medication&#xD;
&#xD;
          -  Known allergy to stainless steel or nickel&#xD;
&#xD;
          -  Magnetic Resonance Imaging (MRI) within 8 weeks of Reducer implantation&#xD;
&#xD;
          -  Participation in another ongoing investigational trial&#xD;
&#xD;
          -  Additional factors deemed unsuitable for trial enrollment per discretion of principal&#xD;
             investigator&#xD;
&#xD;
          -  Inmates&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amir Lerman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diana P Albers, BS</last_name>
    <phone>507-255-6884</phone>
    <email>albers.diana2@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jacob Bjerke</last_name>
    <phone>507-422-0467</phone>
    <email>bjerke.jacob@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana P Albers, BS</last_name>
      <phone>507-255-6884</phone>
      <email>albers.diana2@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jacob Bjerke</last_name>
      <phone>507-422-0467</phone>
      <email>bjerke.jacob@mayo.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 19, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Amir Lerman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

